DermBiont, Inc. is a biotechnology company focused on developing skin microbial therapeutics aimed at treating, curing, and preventing skin diseases. Founded in 2017 and headquartered in Boston, Massachusetts, with an additional office in Emeryville, California, DermBiont operates at the intersection of dermatology and the microbiome. The company leverages naturally occurring microbes on human skin, which have evolved to combat pathogenic microorganisms, including fungi and bacteria. Its product pipeline includes innovative topical treatments for conditions such as fungal infections, seborrheic keratoses, and melasma, utilizing a proprietary skin microbiome library and development platform. DermBiont's therapeutics aim to offer safe and effective solutions, with promising efficacy data from clinical trials.
Chromaderm develops a topical inhibitor of melanin production as a first-in-class therapy for skin brightening, melasma, and other skin diseases associated with increased melanin production.
SeylanMED is a biotech company that develops a targeted therapy for Seborrheic Keratosis. SeylanMED is committed to the development of a topical Akt inhibitor as a first in class treatment for Seborrheic Keratosis (SK). Our lead drug candidate, SM-020, is the first molecularly-targeted approach for the treatment of SK. SeylanMED is funded by angel investors including board-certified dermatologists.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.